Ziccum AB Logo

Ziccum AB

ZICC | ST

Overview

Corporate Details

ISIN(s):
SE0011415595 (+3 more)
LEI:
5493005TADJBZHXP0U27
Country:
Sweden
Address:
Scheelevägen 22, 223 63 Lund
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Ziccum AB develops and licenses its proprietary drying technology, LaminarPace®. This platform uses mass transfer at ambient temperatures to formulate sensitive biologics and vaccines into thermostable, particle-engineered dry powders. The process avoids heat-related degradation, preserving the substance's efficacy and eliminating the need for complex cold chain logistics. The resulting powders are also suitable for novel administration routes. Ziccum's business model is focused on entering into license agreements and technology transfers with major pharmaceutical and biotherapeutic companies to integrate its technology into their product development and manufacturing.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Ziccum AB. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Ziccum AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Ziccum AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-12-13 Ann Gidner Other Buy 14,000 8,381.80 SEK

Peer Companies

Company Country Ticker View
Cantargia Logo
Develops antibody-based drugs targeting IL1RAP for cancer and inflammatory diseases.
Sweden CANTA
Captor Therapeutics S.A. Logo
Develops TPD drugs for oncology and autoimmune disorders, targeting 'undruggable' proteins.
Poland CTX
Developing engineered cellular medicines for regenerative treatment of heart failure.
United Kingdom N/A
Cellectis Logo
Biopharma using gene-editing to create off-the-shelf CAR T-cell cancer therapies.
France ALCLS
Celyad Oncology SA Logo
Clinical-stage biotech developing allogeneic & autologous CAR T-cell therapies for cancer.
Belgium CYAD
Cereno Scientific AB Logo
Clinical-stage biotech developing treatments for rare cardiovascular & pulmonary diseases.
Sweden CRNO
Ceres Power Holdings PLC Logo
Licensing solid oxide tech (SOFC/SOEC) for clean power and green hydrogen to global partners.
United Kingdom CWR
Cessatech A/S Logo
Develops non-invasive pain relief, like a nasal spray, for children.
Denmark CESSA
CHOSA Oncology AB Logo
Develops diagnostics and drug delivery for personalized cancer therapy.
Sweden CHOSA
Cinclus Pharma Holding AB Logo
Late-stage pharma developing a next-gen P-CAB drug for severe GERD and H. pylori.
Sweden CINPHA